📊 NUS Key Takeaways
Is Nu Skin Enterprises, Inc.. (NUS) a Good Investment?
Nu Skin demonstrates solid profitability with strong margins (69.4% gross, 10.8% net) and healthy ROE/ROA, but faces significant headwinds from 14.3% revenue decline YoY, indicating market challenges or structural demand issues. The dramatic net income surge (+209.3% YoY) appears driven by non-operational items rather than sustainable business growth, warranting cautious evaluation of earnings quality.
Revenue is contracting double digits and operating profitability is thin, while the sharp jump in net income appears driven by non-operating items and is not supported by cash flow. The balance sheet is solid with low leverage and good liquidity, but weak cash conversion and declining sales undermine earnings quality and durability.
Why Buy Nu Skin Enterprises, Inc.. Stock? NUS Key Strengths
- Exceptionally high gross margin of 69.4% indicates strong pricing power and cost management
- Solid balance sheet with 2.08x current ratio, 0.25x debt/equity, and adequate liquidity (238.6M cash)
- Strong returns on equity (19.9%) and assets (11.4%) demonstrate efficient capital deployment
- Healthy interest coverage of 3.2x indicates manageable debt burden
- Strong liquidity (2.08x current, 1.40x quick) with cash exceeding long-term debt
- Low leverage (0.25x D/E) and adequate interest coverage (3.2x)
- High gross margin (69.4%) providing cost headroom
NUS Stock Risks: Nu Skin Enterprises, Inc.. Investment Risks
- Significant 14.3% YoY revenue decline suggests serious headwinds in core business or market saturation in wellness/beauty sector
- Operating margin of only 4.4% is concerning given 69.4% gross margin, indicating operational inefficiency or high SG&A expenses
- Net income surge (+209.3% YoY) disconnected from revenue trend raises quality-of-earnings concerns; likely one-time gains or tax benefits
- Free cash flow margin of only 3.1% despite double-digit net margins indicates potential working capital or capex pressures
- 21 Form 4 insider filings in 90 days may indicate high turnover or potential shareholder concerns
- Sustained top-line decline (-14.3% YoY) indicates demand pressure
- Thin operating margin (4.4%) and modest coverage heighten downside risk
- Earnings quality concerns: net margin far above operating margin and OCF well below NI, resulting in low FCF margin (3.1%)
Key Metrics to Watch
- Revenue trend reversal - critical to confirm if decline stabilizes or accelerates
- Operating margin expansion - must improve substantially given margin degradation vs. gross profit
- Operating cash flow sustainability - free cash flow must normalize relative to net income
- Gross margin stability - key competitive advantage that must be protected
- Debt reduction progress - opportunity to optimize capital structure given conservative leverage
- YoY revenue growth and operating margin
- Operating cash flow to net income (cash conversion)
Nu Skin Enterprises, Inc.. (NUS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The relatively thin 3.1% FCF margin may limit capital allocation flexibility. Strong liquidity with a 2.08x current ratio provides a solid financial cushion.
NUS Profit Margin, ROE & Profitability Analysis
NUS vs Market Sector: How Nu Skin Enterprises, Inc.. Compares
How Nu Skin Enterprises, Inc.. compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Nu Skin Enterprises, Inc.. Stock Overvalued? NUS Valuation Analysis 2026
Based on fundamental analysis, Nu Skin Enterprises, Inc.. has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Nu Skin Enterprises, Inc.. Balance Sheet: NUS Debt, Cash & Liquidity
NUS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Nu Skin Enterprises, Inc..'s revenue has declined by 27% over the 5-year period, indicating business contraction. The most recent EPS of $0.17 reflects profitable operations.
NUS Revenue Growth, EPS Growth & YoY Performance
NUS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $364.2M | $8.3M | $0.17 |
| Q2 2025 | $386.1M | $21.1M | $0.43 |
| Q1 2025 | $364.5M | -$533.0K | $-0.01 |
| Q3 2024 | $430.1M | $1.3M | $0.03 |
| Q2 2024 | $439.1M | $26.9M | $0.54 |
| Q1 2024 | $417.3M | -$533.0K | $-0.01 |
| Q3 2023 | $498.8M | $1.3M | $0.03 |
| Q2 2023 | $500.3M | $26.9M | $0.54 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Nu Skin Enterprises, Inc.. Dividends, Buybacks & Capital Allocation
NUS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Nu Skin Enterprises, Inc.. (CIK: 0001021561)
📋 Recent SEC Filings
❓ Frequently Asked Questions about NUS
What is the AI rating for NUS?
Nu Skin Enterprises, Inc.. (NUS) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 64% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are NUS's key strengths?
Claude: Exceptionally high gross margin of 69.4% indicates strong pricing power and cost management. Solid balance sheet with 2.08x current ratio, 0.25x debt/equity, and adequate liquidity (238.6M cash). ChatGPT: Strong liquidity (2.08x current, 1.40x quick) with cash exceeding long-term debt. Low leverage (0.25x D/E) and adequate interest coverage (3.2x).
What are the risks of investing in NUS?
Claude: Significant 14.3% YoY revenue decline suggests serious headwinds in core business or market saturation in wellness/beauty sector. Operating margin of only 4.4% is concerning given 69.4% gross margin, indicating operational inefficiency or high SG&A expenses. ChatGPT: Sustained top-line decline (-14.3% YoY) indicates demand pressure. Thin operating margin (4.4%) and modest coverage heighten downside risk.
What is NUS's revenue and growth?
Nu Skin Enterprises, Inc.. reported revenue of $1.5B.
Does NUS pay dividends?
Nu Skin Enterprises, Inc.. pays dividends, with $11.8M distributed to shareholders in the trailing twelve months.
Where can I find NUS SEC filings?
Official SEC filings for Nu Skin Enterprises, Inc.. (CIK: 0001021561) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is NUS's EPS?
Nu Skin Enterprises, Inc.. has a diluted EPS of $3.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is NUS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Nu Skin Enterprises, Inc.. has a SELL rating with 64% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is NUS stock overvalued or undervalued?
Valuation metrics for NUS: ROE of 19.9% (sector avg: 15%), net margin of 10.8% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy NUS stock in 2026?
Our dual AI analysis gives Nu Skin Enterprises, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is NUS's free cash flow?
Nu Skin Enterprises, Inc..'s operating cash flow is $80.3M, with capital expenditures of $34.3M. FCF margin is 3.1%.
How does NUS compare to other Market stocks?
Vs Default sector averages: Net margin 10.8% (avg: 12%), ROE 19.9% (avg: 15%), current ratio 2.08 (avg: 1.8).